Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +27.42%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Zilliqa Zilliqa +15.74%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Pharos Pharos +14.68%
#9 Taiko Taiko +14.38%
#10 Cap Cap +13.75%
Coin of the day
Orochi Network Orochi Network
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rang în acțiuni #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Preț acțiune
$50.93
Capitalizare de piață
$226.32B
Schimbare (1 zi)
2.54%
Schimbare (1 an)
-26.19%
Țară
DK
Tranzacționează Novo Nordisk A/S (NVO)

Categorie

Healthcare
Venituri pentru Novo Nordisk A/S (NVO)
Venituri în Mar 2026 TTM: $52.05B
Conform celor mai recente rapoarte financiare ale Novo Nordisk A/S, venitul actual al companiei (TTM) este $52.05B. În anul 2024, compania a avut un venit de $40.52B o creștere față de venitul din anul 2023, care a fost de $34.39B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Novo Nordisk A/S din 2000 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $52.05B 11.49%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B -76.45%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B -71.33%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -82.55%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $4.94B -90.50%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
 $4.29B -91.76%
US